Bio-Path Holdings Inc (BPTH) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $5. Rodman & Renshaw advised their investors in a research report released on Apr 18, 2016.
Bio-Path Holdings Inc opened for trading at $2.8 and hit $2.8 on the upside on Friday, eventually ending the session at $2.76, with a gain of 0.36% or 0.01 points. The heightened volatility saw the trading volume jump to 1,44,683 shares. Company has a market cap of $248 M.
In a different news, on Jul 15, 2015, Michael J. Garrison (director) purchased 7,343 shares at $1.22 per share price.
Bio-Path Holdings Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer drugs under a license arrangement. The Company’s lead cancer drug candidate Liposomal Grb-2 (L-Grb-2 or BP1001) is undergoing clinical trials. The Company’s two liposomal antisense drug candidates are focused to treat acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) chronic myelogenous leukemia (CML) acute lymphoblastic leukemia (ALL) and follicular lymphoma. BP1001 is its lead liposome delivered antisense drug candidate which has been clinically tested in patients having AML CML MDS and ALL. BP-100-1.02 (Bcl-2 or BP1002) is its second liposome delivered antisense drug candidate. Clinical targets for BP1002 include lymphoma breast cancer colon cancer prostate cancer and leukemia. The Company has a drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense.